1054 related articles for article (PubMed ID: 15935238)
1. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic and health outcome comparison of lithium and divalproex in a VA geriatric nursing home population: influence of drug-related morbidity on total cost of treatment.
Conney J; Kaston B
Am J Manag Care; 1999 Feb; 5(2):197-204. PubMed ID: 10346515
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder.
Keck PE; Nabulsi AA; Taylor JL; Henke CJ; Chmiel JJ; Stanton SP; Bennett JA
J Clin Psychiatry; 1996 May; 57(5):213-22. PubMed ID: 8626353
[TBL] [Abstract][Full Text] [Related]
4. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder.
McElroy SL; Bowden CL; Collins MA; Wozniak PJ; Keck PE; Calabrese JR
J Affect Disord; 2008 Apr; 107(1-3):127-33. PubMed ID: 17888516
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
Dardennes R; Lafuma A; Watkins S
Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
[TBL] [Abstract][Full Text] [Related]
6. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.
Frye MA; Altshuler LL; Szuba MP; Finch NN; Mintz J
J Clin Psychiatry; 1996 Jan; 57(1):17-21. PubMed ID: 8543542
[TBL] [Abstract][Full Text] [Related]
7. Health-economic implications of the onset of action of antimanic agents.
Keck PE; McElroy SL; Bennett JA
J Clin Psychiatry; 1996; 57 Suppl 13():13-8; discussion 19-22. PubMed ID: 8970501
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
Vieta E; Suppes T; Eggens I; Persson I; Paulsson B; Brecher M
J Affect Disord; 2008 Aug; 109(3):251-63. PubMed ID: 18579216
[TBL] [Abstract][Full Text] [Related]
9. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder.
Kowatch RA; Suppes T; Carmody TJ; Bucci JP; Hume JH; Kromelis M; Emslie GJ; Weinberg WA; Rush AJ
J Am Acad Child Adolesc Psychiatry; 2000 Jun; 39(6):713-20. PubMed ID: 10846305
[TBL] [Abstract][Full Text] [Related]
10. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
11. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania.
Yatham LN; Vieta E; Young AH; Möller HJ; Paulsson B; Vågerö M
Int Clin Psychopharmacol; 2007 Jul; 22(4):212-20. PubMed ID: 17519644
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
[TBL] [Abstract][Full Text] [Related]
13. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
Sussman N; Mullen J; Paulsson B; Vågerö M
J Affect Disord; 2007; 100 Suppl 1():S55-63. PubMed ID: 17383736
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.
Qiu Y; Fu AZ; Liu GG; Christensen DB
Appl Health Econ Health Policy; 2010; 8(3):167-77. PubMed ID: 20408601
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder.
Goodwin FK
J Clin Psychiatry; 2003; 64 Suppl 5():18-24. PubMed ID: 12720480
[TBL] [Abstract][Full Text] [Related]
16. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and HRQOL outcomes of divalproex sodium (Depakote) in bipolar disorder.
Revicki DA
Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):9-14. PubMed ID: 19807331
[TBL] [Abstract][Full Text] [Related]
18. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
Roick C; Ahrens B; Becker T
Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
[TBL] [Abstract][Full Text] [Related]
19. [Prediction of treatment response in acute mania: controlled clinical trials with divalproex].
Swann AC
Encephale; 2001; 27(3):277-9. PubMed ID: 11488258
[TBL] [Abstract][Full Text] [Related]
20. Divalproex sodium in the treatment of refractory affective disorders.
Schaff MR; Fawcett J; Zajecka JM
J Clin Psychiatry; 1993 Oct; 54(10):380-4. PubMed ID: 8262880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
